Your session is about to expire
What is Mitoxantrone Hydrochloride
MitoxantroneThe Generic name of this drug
Treatment SummaryAn antineoplastic agent derived from anthracenedione, a type of chemical compound.
Novantroneis the brand name
Mitoxantrone Hydrochloride Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Novantrone
Mitoxantrone
1987
12
Approved as Treatment by the FDA
Mitoxantrone, otherwise known as Novantrone, is approved by the FDA for 17 uses which include Relapsing Remitting Multiple Sclerosis (RRMS) and Relapsed Leukemia .Relapsing Remitting Multiple Sclerosis (RRMS)
Helps manage Relapsing Remitting Multiple Sclerosis (RRMS)
Relapsed Leukemia
Metastatic Breast Cancer
Secondary Progressive Multiple Sclerosis (SPMS)
Helps manage Secondary Progressive Multiple Sclerosis (SPMS)
Progressive Relapsing Multiple Sclerosis
Helps manage Progressive Relapsing Multiple Sclerosis
Relapsed Lymphomas
Acute Myeloid Leukemia (AML)
Used to treat Acute Myeloid Leukemia (AML) in combination with null
relapsed Hepatocellular carcinoma
Leukemia
Multiple Sclerosis
Helps manage Secondary Progressive Multiple Sclerosis (SPMS)
Liver carcinoma
Metastatic Breast Cancer
Advance Directives
Multiple Sclerosis
Helps manage Progressive Relapsing Multiple Sclerosis
Lymphoma
Acute Myeloid Leukemia
Used to treat Acute Myeloid Leukemia (AML) in combination with null
Relapsing Remitting Multiple Sclerosis
Helps manage Relapsing Remitting Multiple Sclerosis (RRMS)
Effectiveness
How Mitoxantrone Hydrochloride Affects PatientsIn laboratory tests, mitoxantrone has been found to stop the growth of B cells, T cells, and macrophages and reduce the activity of certain proteins involved in immunity. It also reduces the amount of interferon gamma, TNFa, and IL-2 that are released from these cells.
How Mitoxantrone Hydrochloride works in the bodyMitoxantrone works by binding to DNA and interfering with the repair process. It binds to DNA, preventing the enzyme responsible for fixing DNA from doing its job. This stops the cell from being able to fix itself, leading to cell death. It affects both growing and inactive cells, so it is not specific to any particular stage of the cell cycle.
When to interrupt dosage
The amount of Mitoxantrone Hydrochloride is contingent upon the diagnosed state, including Metastatic Breast Cancer, Acute Promyelocytic Leukemia and Advance Directives. The dosage fluctuates as per the route of administration (e.g. Liquid or Injection, solution, concentrate) specified in the table hereunder.Condition
Dosage
Administration
Advance Directives
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Relapsing Remitting Multiple Sclerosis
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Lymphoma
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Multiple Sclerosis
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Hodgkin's Lymphoma
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Liver carcinoma
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Leukemia
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Non-Hodgkin's Lymphoma
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Acute Myeloid Leukemia
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Metastatic Breast Cancer
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Acute Lymphoblastic Leukemia
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Multiple Sclerosis
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Acute Promyelocytic Leukemia
, 2.0 mg/mL, 2.5 mg/mL, 3.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Liquid - Intravenous, Liquid, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Warnings
There are 20 known major drug interactions with Mitoxantrone Hydrochloride.Common Mitoxantrone Hydrochloride Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Acteoside.
Mitoxantrone Hydrochloride Toxicity & Overdose RiskAn overdose on this drug can cause a severe decrease in white blood cells, which can lead to an increased risk of infection.
Mitoxantrone Hydrochloride Novel Uses: Which Conditions Have a Clinical Trial Featuring Mitoxantrone Hydrochloride?
Presently, 785 active studies are being conducted to examine the efficacy of Mitoxantrone Hydrochloride in treating Hodgkin's Lymphoma, Metastatic Breast Cancer and Relapsed Lymphomas.Condition
Clinical Trials
Trial Phases
Lymphoma
1 Actively Recruiting
Phase 2
Acute Myeloid Leukemia
271 Actively Recruiting
Phase 2, Phase 1, Phase 3, Phase 4, Not Applicable, Early Phase 1
Multiple Sclerosis
12 Actively Recruiting
Phase 3, Phase 2, Not Applicable, Early Phase 1, Phase 1
Liver carcinoma
0 Actively Recruiting
Relapsing Remitting Multiple Sclerosis
33 Actively Recruiting
Phase 3, Phase 4, Phase 2, Not Applicable, Phase 1, Early Phase 1
Leukemia
1 Actively Recruiting
Phase 1, Phase 2
Acute Promyelocytic Leukemia
0 Actively Recruiting
Metastatic Breast Cancer
1 Actively Recruiting
Phase 1, Phase 2
Advance Directives
0 Actively Recruiting
Multiple Sclerosis
0 Actively Recruiting
Non-Hodgkin's Lymphoma
120 Actively Recruiting
Phase 1, Phase 2, Early Phase 1, Not Applicable, Phase 3
Acute Lymphoblastic Leukemia
117 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4
Hodgkin's Lymphoma
67 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1
Mitoxantrone Hydrochloride Reviews: What are patients saying about Mitoxantrone Hydrochloride?
5Patient Review
6/20/2009 After years of taking Rebif, my neurologist recommended this treatment to me. I was terrified of progressing to advanced RRMS andsecondary progressive MS, but after two years on the chemo with no side effects, my EDSS score went from 4.5 to 2.
3.7Patient Review
5/18/2009Patient Q&A Section about mitoxantrone hydrochloride
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What kind of chemo is mitoxantrone?
"Mitoxantrone is an anti-cancer drug that is classified as an "antitumor antibiotic.""
Answered by AI
How does mitoxantrone work in the body?
"Mitoxantrone is an injection that falls into the category of medications known as anthracenediones. This particular medication works to treat MS by hindering certain cells of the immune system from being able to reach the brain and spinal cord where they can cause damage. As for cancer, mitoxantrone work by stopping the growth and spread of cancer cells."
Answered by AI
What is mitoxantrone used for?
"Mitoxantrone injection is a medication used to treat advanced prostate cancer and acute nonlymphocytic leukemia. It is typically used in conjunction with other medications and belongs to a group of medications known as antineoplastics or cancer medications. Mitoxantrone is also sometimes used to treat multiple sclerosis."
Answered by AI
How long does mitoxantrone take to work?
"The average response time to mitoxantrone chemotherapy was 21 days, with 7 out of 15 dogs experiencing complete responses that lasted an average of 84 days."
Answered by AI